Commercializing cell and gene therapies

New business models for clinical development and manufacturing require strategic partnerships among researchers, manufacturers and payers to fully realize the commercial opportunities.

[video src="https://www.youtube-nocookie.com/embed/nnvhUGUnqWY?rel=0"]
Moderator: Morrie Ruffin – Adjuvant Partners

• Boro Dropulic – Lentigen Technology Inc., A Miltenyi Biotec Company
• Miguel Mulet – TiGenix NV
• Peter Nell – Casebia Therapeutics